3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
72
Lung Neoplasms
34
Squamous Cell Carcinoma of Head and Neck
32
Head and Neck Neoplasms
30
Urinary Bladder Neoplasms
19
Uterine Cervical Neoplasms
18
Stomach Neoplasms
17
Esophageal Neoplasms
17
Small Cell Lung Carcinoma
16
Cholangiocarcinoma
16
Neoplasm Metastasis
13
Ovarian Neoplasms
12
Carcinoma, Squamous Cell
11
Breast Neoplasms
11
Neoplasms
10
Mesothelioma, Malignant
9
Esophageal Squamous Cell Carcinoma
8
Biliary Tract Neoplasms
8
Sarcoma
7
Fallopian Tube Neoplasms
7
Pancreatic Neoplasms
6
Mesothelioma
6
Adenocarcinoma of Lung
6
Adenocarcinoma Of Esophagus
6
Recurrence
5
Gallbladder Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Bile Duct Neoplasms
5
Triple Negative Breast Neoplasms
4
Osteosarcoma
4
Interventions
umbralisib
1
ublituximab
1
marizomib
1
fludarabine phosphate
1
fludarabine
1
enzastaurin
1
durvalumab
1
carotuximab
1
brigatinib
1
binimetinib
1
axicabtagene ciloleucel
1
Zoledronic Acid
1
Vitamin D
1
Receptors, Interleukin-6
1
Oxaliplatin
1
Leucovorin
1
Irinotecan
1
Interleukin 1 Receptor Antagonist Protein
1
Gemcitabine
1
Folfox protocol
1
Fluorouracil
1
Cyclophosphamide
1
Cisplatin
1
Calcium
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Disease Progression
×
Cisplatin
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts